分类： 医学、药学 >> 基础医学 提交时间： 2017-12-27 合作期刊: 《南方医科大学学报》
摘要： Objective Whether statins can slow down the progression of chronic kidney disease (CKD) remains controversial. We performed a meta-analysis to evaluate the effects of statin therapy on disease progression in adult patients with CKD who did not require dialysis therapy. Methods We searched the electronic databases for relevant randomized controlled trials (RCTs) published by February 2015. Random-effects meta-analysis of RCTs was used to pool the renal outcomes of the patients. Results Twenty-eight studies (30 RCTs) involving a total of 45 688 participants were included in the analysis. Compared with the control groups, statins produced no effects in preventing end-stage renal disease (ESRD) [relative risks (RR) 0.98, 95% confidence intervals (CI): 0.91-1.05] and in reducing the risk of doubling of the serum creatinine level (RR 1.43, 95% CI: 0.26-7.79). Statin therapy was associated with a lowered risk of estimated glomerular filtration rate (eGFR) reduction by 25% or more (RR 0.91, 95% CI: 0.83-0.99) and delayed the reduction of eGFR [standardized mean differences (SMD) 0.04, 95% CI: 0.02-0.07]. In subgroup analyses, the benefit of statins on changes in eGFR was statistically significant in patients with moderate CKD (SMD 0.09, 95% CI 0.04-0.13). Among different statins, atorvastatin was associated with a beneficial effect on kidney function (SMD 0.10, 95% CI 0.03-0.17). Patients who received high-intensity statin therapy showed significant changes in eGFR (SMD 0.12, 95% CI: 0.02-0.21). Conclusion Statin therapies may not prevent ESRD or doubling of serum creatinine level, but can improve GFR or delay the reduction of GFR in CKD patients. The therapeutic effects are associated with the patients' baseline eGFR levels, statin types and therapy intensity.
分类： 医学、药学 >> 基础医学 提交时间： 2017-12-07 合作期刊: 《南方医科大学学报》
摘要： 微生物组学是新兴学科，与肠道、代谢、生殖、神经等大量慢性疾病相关。通过测序分析微生物组，主要包括16S rRNA和宏基因组两大技术。16S rRNA数据分析主要包括序列处理、样品多样性分析及统计分析3个步骤。宏基因组数据分析主要包括序列处理、分类、注释及统计分析4个环节。随着测序技术的升级，测序成本将逐步降低，而大数据分析将成为核心内容。数据的标准化和可积累性、通过数据建模和预测疾病的发生发展是未来应用的基础，数据知识产权保护以及数据本身价值的开发与保护价值将日益显现，培养和基于培养的功能验证将是未来的重点之一。人体微生物组学将阐述并调整人与微生物组之间的关系，此领域相关研究有巨大的发展空间
点击量
点击量
下载量
评论
